List of Excipients in Branded Drug TUSSIONEX PENNKINETIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Unither Manufacturing LLC	TUSSIONEX PENNKINETIC	hydrocodone polistirex and chlorpheniramine polistirex	53014-548	ASCORBIC ACID
Unither Manufacturing LLC	TUSSIONEX PENNKINETIC	hydrocodone polistirex and chlorpheniramine polistirex	53014-548	D&C YELLOW NO. 10
Unither Manufacturing LLC	TUSSIONEX PENNKINETIC	hydrocodone polistirex and chlorpheniramine polistirex	53014-548	ETHYLCELLULOSE

Tussionex Pennkinetic Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Tussionex Pennkinetic is an extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex. Its commercial differentiation depends on the Pennkinetic resin-complex delivery system, 12-hour dosing, taste masking, suspension stability, and controlled release rather than on a conventional immediate-release syrup platform. The strongest commercial opportunities are sugar-reduced or sugar-free reformulations, improved dosing presentations, preservative and colorant alternatives, and generic or authorized-generic products that reproduce the release and abuse-risk profile without copying every excipient.

What is Tussionex Pennkinetic and how does the formulation work?

Tussionex Pennkinetic is a prescription extended-release antitussive and antihistamine suspension. Each 5 mL dose contains:

Active ingredient	Salt or complex	Equivalent active amount
Hydrocodone	Hydrocodone polistirex	10 mg hydrocodone
Chlorpheniramine	Chlorpheniramine polistirex	8 mg chlorpheniramine

The product is administered every 12 hours, subject to the prescribing information. The label identifies the Pennkinetic system as an extended-release delivery platform based on drug-resin complexes. The resin complexes help control drug release, mask the bitter taste of the active ingredients, and allow the product to remain in a liquid suspension suitable for oral dosing.[1]

The formulation is not a simple hydrocodone syrup. Its performance depends on several linked attributes:

1. Drug loading onto or association with the resin.
2. Particle-size distribution of the drug-resin complex.
3. Release kinetics in gastrointestinal media.
4. Suspension uniformity during storage and dosing.
5. Sedimentation and redispersion behavior.
6. Taste masking and mouthfeel.
7. Chemical and microbiological stability.

A generic or reformulated product that changes the resin, particle size, polymer coating, or suspending system may require substantial comparative data even if the active ingredients remain unchanged.

What excipients are used in Tussionex Pennkinetic?

The FDA-approved labeling identifies the following inactive ingredients:

Excipient or component	Likely formulation role
Cetyl alcohol	Consistency modifier and emulsion or suspension aid
Ethylcellulose	Release-control or coating-related polymer
FD&C Yellow No. 6	Colorant
Flavor	Taste and aroma masking
Gelatin	Resin-complex or coating-related processing component
High-fructose corn syrup	Sweetener and viscosity contributor
Methylparaben	Antimicrobial preservative
Povidone	Binder, dispersant, or processing aid
Propylene glycol	Solvent, humectant, and flavor carrier
Purified water	Vehicle
Saccharin sodium	High-intensity sweetener
Sodium citrate	Buffering and ionic-strength control
Xanthan gum	Suspending and viscosity-enhancing agent

The exact functional role of every ingredient is not fully disclosed in the public label. In a drug-resin suspension, excipient roles can overlap. For example, xanthan gum controls sedimentation and redispersion, while sodium citrate can affect pH, ionic strength, resin interaction, and preservative performance.

High-fructose corn syrup is commercially useful because it improves sweetness, viscosity, and mouthfeel. It also creates positioning constraints for patients seeking lower-sugar products. Methylparaben provides preservation but may limit acceptance in "clean label" or preservative-free segments. FD&C Yellow No. 6 can restrict use in customers avoiding synthetic colorants.

Which excipients create the largest reformulation opportunities?

The highest-value excipient opportunities are those that improve patient acceptability without changing the extended-release profile.

Sugar reduction and sugar-free formulations

Tussionex uses high-fructose corn syrup. A sugar-free version could replace it with a combination of polyols, high-intensity sweeteners, and viscosity modifiers. Candidate systems could include sorbitol, glycerin, maltitol, sucralose, acesulfame potassium, or an adjusted saccharin system.

The technical risk is that sugar replacement changes:

• Density and dose-volume accuracy.
• Suspension viscosity.
• Sedimentation rate.
• Sweetness duration.
• Aftertaste.
• Preservative efficacy.
• Resin-complex release.

A sugar-free product would need comparative dissolution and suspension-performance testing. A formulation that is chemically equivalent but less viscous may produce faster settling and inconsistent dosing.

Preservative alternatives

Methylparaben could be replaced by other preservatives or by a preservative-free multidose system. Candidate approaches include potassium sorbate, sodium benzoate, phenoxyethanol, or a sterile or unit-dose package. Each option has compatibility limits related to pH, sorption to packaging, resin binding, and antimicrobial effectiveness.

A preservative-free single-dose cup or sachet could be commercially attractive for pediatric, institutional, and travel use. The tradeoff is higher packaging cost and reduced flexibility for large-volume dispensing.

Colorant-free products

FD&C Yellow No. 6 is a straightforward target for reformulation. Removing the colorant may reduce excipient sensitivity concerns and support pharmacy or caregiver preferences for a simpler product. The commercial value is more likely to arise from product differentiation than from a broad clinical advantage.

Color removal also creates a visual-control issue. In a suspension, color helps users identify phase separation or gross product changes. A colorless or pale product would need strong labeling and packaging controls for shake-before-use instructions.

Flavor and sweetener optimization

Hydrocodone and chlorpheniramine are both challenging taste-masking targets. Taste is controlled through a combination of resin complexation, flavor, sweetener, viscosity, and mouthfeel. A reformulator should screen flavor systems against:

• Immediate bitterness.
• Delayed bitterness after swallowing.
• Metallic or medicinal notes.
• Excessive throat cooling or warming.
• Residual sweetness.
• Flavor stability over shelf life.

A single flavor profile is unlikely to maximize acceptance across pediatric and adult populations. Separate grape, cherry, or berry variants could increase commercial appeal, but each additional flavor may create regulatory and manufacturing complexity.

How strong is the Pennkinetic formulation barrier?

The formulation barrier is meaningful but not absolute. The active ingredients are old and widely understood, while the extended-release suspension requires replication of a more complex product profile.

Technical barriers

The principal barriers include:

• Reproducing the hydrocodone and chlorpheniramine release curves.
• Maintaining a uniform dose after storage and shaking.
• Matching drug-resin complex particle size.
• Controlling alcohol and food effects.
• Preventing dose dumping.
• Preserving taste masking after reformulation.
• Demonstrating stability in the final container-closure system.

A conventional generic syrup would not be an equivalent substitute because it would not reproduce the 12-hour extended-release profile. The most credible generic path would use a comparable ion-exchange or resin-complex approach with a suspension vehicle engineered around the reference product.

Regulatory barriers

Tussionex is approved under NDA 019111 as a prescription product. A generic applicant would generally pursue an abbreviated new drug application if the product-specific requirements can be satisfied. The applicant would need to address bioequivalence, dissolution or in vitro release, formulation composition, stability, microbiological quality, and device or measuring-cup performance where applicable.[2]

For an extended-release oral suspension, in vitro data may have unusually high importance because the product's clinical performance depends on particle release and suspension behavior. The FDA may also consider alcohol interaction and food-effect risks relevant to an opioid-containing modified-release product.

What is the Orange Book status of Tussionex?

Tussionex's principal commercial protection is formulation know-how and regulatory complexity rather than a durable modern patent estate. Historical Pennkinetic and drug-resin delivery patents are generally old enough to have reached the end of their ordinary patent terms. The relevant regulatory and patent position should be assessed from the current FDA Orange Book entry, the approved labeling, and any listed patent certifications associated with the product.[2]

Key points for market-entry analysis are:

Issue	Commercial implication
Active ingredients	No meaningful composition-of-matter exclusivity remains
Extended-release suspension	Technical replication remains difficult
Drug-resin complexes	May create process and formulation know-how barriers
Method-of-use claims	Could affect specific cough or upper-respiratory indications if listed
Orange Book patents	Must be checked against the current reference-listed drug record
Regulatory exclusivity	Any remaining exclusivity would be more relevant than historical platform patents
Paragraph IV exposure	A generic applicant could challenge any listed unexpired patent

A Paragraph IV challenge would be commercially significant only if the Orange Book lists an unexpired patent covering the product, formulation, or use. If no enforceable listed patent remains, an ANDA applicant's timing would depend primarily on FDA review, patent-law risk outside the Orange Book, manufacturing readiness, and market economics.

When does Tussionex lose exclusivity?

Tussionex's original approval dates to the early NDA era, and any ordinary five-year new-chemical-entity exclusivity has long expired. The active ingredients are established opioid and antihistamine compounds rather than new chemical entities.

The relevant distinction is between:

• Regulatory exclusivity, which is likely historical and expired.
• Patent exclusivity, which depends on any currently listed patents.
• Trade-secret protection, which can continue indefinitely but does not block independent replication.
• Manufacturing advantage, which persists only while the supplier maintains cost, quality, and regulatory execution advantages.

Tussionex therefore operates in a mature-product environment. The commercial question is not whether the product has basic molecule exclusivity. It is whether competitors can reproduce the extended-release suspension at acceptable quality and secure an economically viable market position.

Which companies are positioned to challenge Tussionex?

Potential challengers fall into four groups:

1. Generic manufacturers with controlled-release liquid capabilities.
2. Specialty pharmaceutical companies with ion-exchange resin technology.
3. Contract development and manufacturing organizations with oral suspension expertise.
4. Branded reformulators pursuing sugar-free, preservative-free, or packaging-led differentiation.

The most capable generic applicants are likely to have experience with modified-release oral products, resin complexes, rheology control, and opioid regulatory requirements. A company that specializes only in conventional syrups would face a higher technical risk.

Competition could also come from therapeutic substitutes rather than direct copies. These include non-opioid cough products, dextromethorphan formulations, benzonatate, antihistamine products, and combination cold medicines. Such products do not need to reproduce the Pennkinetic system but compete for the same symptomatic-treatment budget.

What commercial opportunities exist for a Tussionex reformulation?

Premium sugar-free product

A sugar-free product is the clearest line-extension opportunity. It could target patients with sugar restrictions, caregivers seeking lower-sugar medicines, and pharmacies that prefer a differentiated liquid product. The formulation must preserve suspension uniformity and taste because sugar contributes to both.

Unit-dose packaging

Unit-dose cups could reduce dosing errors and improve use in urgent-care, pediatric, institutional, and travel settings. The format would also reduce repeated bottle opening and potentially support preservative reduction.

The disadvantages are higher packaging costs, more complex filling operations, and potentially greater exposure to controlled-substance diversion controls.

Improved oral dosing system

A calibrated oral syringe, rather than a household teaspoon or generic dosing cup, could improve dosing accuracy. A redesigned package could combine:

• An adapter compatible with an oral syringe.
• A child-resistant closure.
• A visible shake-before-use instruction.
• Tamper evidence.
• A measured-dose presentation.

The commercial benefit would be strongest if supported by human-factors data and clear labeling.

Preservative-free or low-excipient product

A preservative-free version could address caregiver preferences and institutional procurement requirements. The most credible format would be single-dose packaging rather than a conventional multidose bottle.

Opioid-risk positioning

Because hydrocodone is a Schedule II opioid, any commercial strategy must account for controlled-substance scrutiny. Abuse-deterrent positioning would require substantial evidence and would not arise merely from the presence of a resin complex. A company should not assume that taste masking or extended release qualifies the product as abuse-deterrent under FDA standards.[3]

What formulation patents could protect a new Tussionex product?

A new product could potentially support patent claims directed to:

• Specific drug-resin complex particle sizes.
• Polymer-coated resin complexes.
• Defined hydrocodone-to-resin or chlorpheniramine-to-resin ratios.
• Sugar-free suspension systems.
• Preservative-free multidose systems.
• Improved redispersion profiles.
• Reduced alcohol dose-dumping effects.
• Packaging that delivers a controlled volume.
• Specific combinations of rheology modifiers and sweeteners.
• Manufacturing processes that produce a defined release profile.

A new patent estate would be strongest when claims link composition to measurable performance, such as release-rate ranges, sedimentation limits, or dose uniformity after a defined shaking protocol. Broad claims covering only familiar excipients are more vulnerable to obviousness challenges.

Method-of-use claims could target 12-hour symptomatic relief, specific patient populations, or dosing schedules, but their value would depend on the scope of the approved indication and the ability to detect or enforce infringement.

How does Tussionex compare with competing cough products?

Product category	Release profile	Opioid exposure	Liquid format	Main commercial advantage
Tussionex Pennkinetic	Extended release	Hydrocodone	Yes	12-hour dosing and combined antitussive-antihistamine effect
Immediate-release opioid cough products	Immediate release	Often present	Often yes	Lower formulation complexity
Dextromethorphan products	Usually immediate release	No	Common	Lower controlled-substance burden
Benzonatate	Immediate release capsule	No	No	Non-opioid mechanism
Antihistamine-only products	Immediate or extended release	No	Some	Symptom-specific treatment

Tussionex's differentiation is strongest where prescribers value extended dosing and a liquid presentation. Its disadvantages are controlled-substance restrictions, opioid safety concerns, and the technical cost of reproducing the formulation.

What revenue exposure and licensing opportunities exist?

Public sources do not provide a reliable standalone revenue figure for Tussionex. The commercial opportunity is better assessed through prescription volume, average net price, generic entry timing, payer coverage, and the percentage of demand retained by the branded product after a generic launch.

Licensing opportunities include:

• A resin-complex platform license for a generic applicant.
• A sugar-free or preservative-free reformulation license.
• A regional commercialization deal for a liquid controlled-substance product.
• A contract manufacturing agreement for the suspension and drug-resin complex.
• A co-development arrangement involving an oral dosing device.

The most defensible licensing asset would be a validated formulation and process package that reduces ANDA development time. A mere excipient list has limited standalone value because many listed excipients are commercially available and can be substituted.

What generic launch scenarios exist?

Scenario 1: No direct generic

The reference product retains share because few manufacturers accept the technical and controlled-substance burden. In this scenario, excipient innovation can support premium pricing and defend the brand through patient acceptability.

Scenario 2: One approved generic

A single generic could produce moderate price erosion while leaving room for a branded sugar-free or device-enhanced product. The reference product would need to maintain prescriber and pharmacy preference.

Scenario 3: Multiple generic entrants

Several ANDA approvals could sharply reduce price and increase substitution. The brand's most defensible response would be a differentiated formulation or package with a separate regulatory basis, not a minor flavor change.

Scenario 4: Therapeutic substitution

Non-opioid cough products gain share because of prescribing restrictions or safety concerns. In this case, a Tussionex reformulation may have limited value unless it addresses a specific adherence or dosing problem.

Key Takeaways

• Tussionex Pennkinetic is an extended-release suspension of hydrocodone polistirex and chlorpheniramine polistirex.
• The formulation's core value lies in the drug-resin delivery system, release control, taste masking, and suspension performance.
• High-fructose corn syrup, methylparaben, and FD&C Yellow No. 6 are the clearest excipient targets for commercial reformulation.
• A sugar-free, preservative-free, colorant-free, or unit-dose product could support premium positioning.
• Generic entry is technically more difficult than entry into an immediate-release cough syrup.
• Historical platform patents are unlikely to provide current long-term exclusivity; the current Orange Book record controls listed-patent analysis.
• New patent value would come from defined resin, particle-size, release, suspension, packaging, or manufacturing claims.
• Hydrocodone scheduling and FDA opioid controls materially affect development, distribution, and licensing economics.
• The strongest business opportunity is a validated reformulation or manufacturing package, not an undifferentiated excipient substitution.

FAQs

Can Tussionex be reformulated without using high-fructose corn syrup?

Yes. A sugar-free vehicle can use polyols and high-intensity sweeteners, but the replacement must preserve viscosity, suspension uniformity, taste, preservative effectiveness, and drug-release behavior.

Does the Pennkinetic system make Tussionex abuse-deterrent?

No automatic conclusion follows from the Pennkinetic name or from resin complexation. Abuse-deterrent status requires product-specific evidence and FDA evaluation under applicable guidance.[3]

Is a generic Tussionex likely to use the same excipients?

Not necessarily. A generic applicant may use different excipients if it demonstrates pharmaceutical equivalence, bioequivalence, stability, and comparable performance under the applicable FDA requirements.

What is the most valuable new patent claim for a Tussionex successor?

Claims tied to a defined release profile, resin-complex particle distribution, improved redispersion, or a sugar-free vehicle are more commercially meaningful than broad claims covering common sweeteners or suspending agents.

Could a unit-dose Tussionex product reduce controlled-substance risk?

Unit-dose packaging may improve dose control, tamper evidence, inventory reconciliation, and dispensing management. It does not eliminate the regulatory obligations associated with hydrocodone.

References

1. U.S. Food and Drug Administration. (n.d.). Tussionex Pennkinetic extended-release suspension prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2015). Industry guidance: Abuse-deterrent opioids: Evaluation and labeling. U.S. Department of Health and Human Services.